Pfizer pays record fine for off-label promotion of four drugs

BMJ 2009; 339 doi: 10.1136/bmj.b3657 (Published 9 September 2009)
Cite this as: BMJ 2009;339:b3657

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. 1New York

    Pfizer, the world’s largest drug company, has agreed to pay $2.3bn (£1.4bn; €1.6bn) to settle charges of fraud and civil and criminal liability over its promotion of off-label use of four drugs.

    The US Department of Justice said it was the largest healthcare fraud settlement in the department’s history and the largest criminal fine ever.

    The New York Times noted that $2.3bn amounted to less than three weeks of Pfizer sales (www.nytimes.com, 3 Sep, “Pfizer to pay $2.3 billion to settle inquiry over marketing”).

    Unlike in previous settlements by drug companies, the announcement of the settlement was made at a Washington press conference by …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL